BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Acute Lymphoblastic Leukemia readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Acute Lymphoblastic L
 eukemia\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03020030-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Methotrexate: Phase 3 readout est. (NCT03020030)
DESCRIPTION:Methotrexate\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and 
 Adolescents\nEstimated primary completion: 30 November 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT03020030
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06207123-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Methotrexate: Phase 1/2 readout est. (NCT06207123)
DESCRIPTION:Methotrexate\, phase 1/2\, Acute Lymphoblastic Leukemia.\nStudy
 : A Study to Investigate LP-118\, Ponatinib\, Vincristine and Dexamethason
 e in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblast
 ic Lymphoma (LBL)\nEstimated primary completion: 1 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06207123
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06207123-10794@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:ICLUSIG (Ponatinib): Phase 1/2 readout est. (NCT06207123)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 1/2\, Acute Lymphoblastic Leukemia.
 \nStudy: A Study to Investigate LP-118\, Ponatinib\, Vincristine and Dexam
 ethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymp
 hoblastic Lymphoma (LBL)\nEstimated primary completion: 1 December 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ponatinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06207123
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03114865-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Blinatumomab: Phase 1/2 readout est. (NCT03114865)
DESCRIPTION:Blinatumomab\, phase 1/2\, Acute Lymphoblastic Leukemia.\nStudy
 : A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL a
 s Post-allo-HSCT Remission Maintenance\nEstimated primary completion: 30 D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/blinatu
 momab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT03114865
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02981628-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Methotrexate: Phase 2 readout est. (NCT02981628)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Ly
 mphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leuke
 mia\nEstimated primary completion: 31 December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT02981628
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06886074-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT06886074)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL\nEstim
 ated primary completion: January 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06886074
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05519579-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Methotrexate: Phase 2 readout est. (NCT05519579)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blin
 atumomab Therapy for Acute Lymphoblastic Leukemia\nEstimated primary compl
 etion: 1 February 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/methotrexate#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05519579
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03739814-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT03739814)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treati
 ng Patients With Newly Diagnosed\, Recurrent\, or Refractory CD22-Positive
  B-Lineage Acute Lymphoblastic Leukemia\nEstimated primary completion: 1 F
 ebruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/blinatu
 momab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT03739814
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05519579-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT05519579)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blin
 atumomab Therapy for Acute Lymphoblastic Leukemia\nEstimated primary compl
 etion: 1 February 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/blinatumomab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05519579
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03739814-10794@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:ICLUSIG (Ponatinib): Phase 2 readout est. (NCT03739814)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 2\, Acute Lymphoblastic Leukemia.\n
 Study: Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in
  Treating Patients With Newly Diagnosed\, Recurrent\, or Refractory CD22-P
 ositive B-Lineage Acute Lymphoblastic Leukemia\nEstimated primary completi
 on: 1 February 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 ponatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT03739814
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03147612-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Methotrexate: Phase 2 readout est. (NCT03147612)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Low-Intensity Chemotherapy\, Ponatinib and Blinatumomab in Treating Patien
 ts With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lym
 phoblastic Leukemia\nEstimated primary completion: 28 February 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT03147612
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03147612-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT03147612)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Low-Intensity Chemotherapy\, Ponatinib and Blinatumomab in Treating Patien
 ts With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lym
 phoblastic Leukemia\nEstimated primary completion: 28 February 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/blinatumomab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT03147612
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03147612-10794@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:ICLUSIG (Ponatinib): Phase 2 readout est. (NCT03147612)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 2\, Chronic Myeloid Leukemia.\nStud
 y: Low-Intensity Chemotherapy\, Ponatinib and Blinatumomab in Treating Pat
 ients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute 
 Lymphoblastic Leukemia\nEstimated primary completion: 28 February 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/ponatinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT03147612
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04329325-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Methotrexate: Phase 2 readout est. (NCT04329325)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadel
 phia Chromosome-Positive Acute Lymphoblastic Leukemia\nEstimated primary c
 ompletion: March 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/methotrexate#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT04329325
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04329325-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT04329325)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadel
 phia Chromosome-Positive Acute Lymphoblastic Leukemia\nEstimated primary c
 ompletion: March 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/blinatumomab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT04329325
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05303792-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Methotrexate: Phase 2 readout est. (NCT05303792)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatu
 momab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B
 -cell Acute Lymphoblastic Leukemia\nEstimated primary completion: 1 April 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/methotrexate#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT053037
 92
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06308588-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Blinatumomab: Phase 1/2 readout est. (NCT06308588)
DESCRIPTION:Blinatumomab\, phase 1/2\, Acute Lymphoblastic Leukemia.\nStudy
 : Phase I/II Study of the Combination of Blinatumomab and Asciminib in Pat
 ients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia\n
 Estimated primary completion: 1 May 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06308588
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07199855-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT07199855)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HS
 CT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia\nEstimated
  primary completion: 1 June 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07199855
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01920737-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Methotrexate: Phase 2 readout est. (NCT01920737)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs f
 or Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblasti
 c Leukemia\nEstimated primary completion: August 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT01920737
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04722848-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Blinatumomab: Phase 3 readout est. (NCT04722848)
DESCRIPTION:Blinatumomab\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and I
 matinib in Newly Diagnosed Adult Ph+ ALL\nEstimated primary completion: Se
 ptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/blinatu
 momab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04722848
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04722848-10794@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:ICLUSIG (Ponatinib): Phase 3 readout est. (NCT04722848)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 3\, Acute Lymphoblastic Leukemia.\n
 Study: Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherap
 y and Imatinib in Newly Diagnosed Adult Ph+ ALL\nEstimated primary complet
 ion: September 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 ponatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04722848
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05327894-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Blinatumomab: Phase 3 readout est. (NCT05327894)
DESCRIPTION:Blinatumomab\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearra
 nged ALL or Mixed Phenotype Acute Leukemia\nEstimated primary completion: 
 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/blina
 tumomab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05327894
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03914625-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Methotrexate: Phase 3 readout est. (NCT03914625)
DESCRIPTION:Methotrexate\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 A Study to Investigate Blinatumomab in Combination With Chemotherapy in Pa
 tients With Newly Diagnosed B-Lymphoblastic Leukemia\nEstimated primary co
 mpletion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/methotrexate#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT03914625
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03914625-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Blinatumomab: Phase 3 readout est. (NCT03914625)
DESCRIPTION:Blinatumomab\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 A Study to Investigate Blinatumomab in Combination With Chemotherapy in Pa
 tients With Newly Diagnosed B-Lymphoblastic Leukemia\nEstimated primary co
 mpletion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/blinatumomab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT03914625
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07723911-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20271010
DTEND;VALUE=DATE:20271011
SUMMARY:Blinatumomab: Phase 3 readout est. (NCT07723911)
DESCRIPTION:Blinatumomab\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R
  CD19+ B-ALL\nEstimated primary completion: 10 October 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07723911
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01424982-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Methotrexate: Phase 2 readout est. (NCT01424982)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients 
 With Acute Lymphoblastic Leukemia\nEstimated primary completion: 31 Octobe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/methotrexate#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0142
 4982
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01424982-10794@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:ICLUSIG (Ponatinib): Phase 2 readout est. (NCT01424982)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 2\, Chronic Myeloid Leukemia.\nStud
 y: Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patien
 ts With Acute Lymphoblastic Leukemia\nEstimated primary completion: 31 Oct
 ober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ponatinib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0142
 4982
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03150693-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Methotrexate: Phase 3 readout est. (NCT03150693)
DESCRIPTION:Methotrexate\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults 
 With Newly Diagnosed B Acute Lymphoblastic Leukemia\nEstimated primary com
 pletion: 1 November 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/methotrexate#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT03150693
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04521231-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20271124
DTEND;VALUE=DATE:20271125
SUMMARY:Blinatumomab: Phase 1/2 readout est. (NCT04521231)
DESCRIPTION:Blinatumomab\, phase 1/2\, Acute Lymphoblastic Leukemia.\nStudy
 : A Study of Subcutaneous Blinatumomab Administration in Participants With
  R/R and MRD+ B-ALL\nEstimated primary completion: 24 November 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/blinatumomab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT04521231
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03263572-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Methotrexate: Phase 2 readout est. (NCT03263572)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Blinatumomab\, Methotrexate\, Cytarabine\, and Ponatinib in Treating Patie
 nts With Philadelphia Chromosome-Positive\, or BCR-ABL Positive\, or Relap
 sed/Refractory\, Acute Lymphoblastic Leukemia\nEstimated primary completio
 n: 30 November 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 methotrexate#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT03263572
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03263572-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT03263572)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Blinatumomab\, Methotrexate\, Cytarabine\, and Ponatinib in Treating Patie
 nts With Philadelphia Chromosome-Positive\, or BCR-ABL Positive\, or Relap
 sed/Refractory\, Acute Lymphoblastic Leukemia\nEstimated primary completio
 n: 30 November 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 blinatumomab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT03263572
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03263572-10794@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:ICLUSIG (Ponatinib): Phase 2 readout est. (NCT03263572)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 2\, Chronic Myeloid Leukemia.\nStud
 y: Blinatumomab\, Methotrexate\, Cytarabine\, and Ponatinib in Treating Pa
 tients With Philadelphia Chromosome-Positive\, or BCR-ABL Positive\, or Re
 lapsed/Refractory\, Acute Lymphoblastic Leukemia\nEstimated primary comple
 tion: 30 November 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/ponatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT03263572
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06390319-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06390319)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly
  Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) O
 r Mixed Phenotype Acute Leukemia (MPAL)\nEstimated primary completion: Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methotrex
 ate#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06390319
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04065399-2841@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Revumenib: Phase 1/2 readout est. (NCT04065399)
DESCRIPTION:Revumenib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Study
  of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rear
 rangement or NPM1 Mutation\nEstimated primary completion: 15 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/revumenib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04065399
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05660473-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Methotrexate: Phase 2 readout est. (NCT05660473)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adu
 lt Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblas
 tic Leukemia\nEstimated primary completion: 15 December 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05660473
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01371630-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20271225
DTEND;VALUE=DATE:20271226
SUMMARY:Methotrexate: Phase 1/2 readout est. (NCT01371630)
DESCRIPTION:Methotrexate\, phase 1/2\, Acute Lymphoblastic Leukemia.\nStudy
 : Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients 
 With Acute Lymphoblastic Leukemia\nEstimated primary completion: 25 Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/methotrexate
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT013
 71630
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01371630-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20271225
DTEND;VALUE=DATE:20271226
SUMMARY:Blinatumomab: Phase 1/2 readout est. (NCT01371630)
DESCRIPTION:Blinatumomab\, phase 1/2\, Acute Lymphoblastic Leukemia.\nStudy
 : Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients 
 With Acute Lymphoblastic Leukemia\nEstimated primary completion: 25 Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/blinatumomab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT013
 71630
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05761171-2841@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Revumenib: Phase 2 readout est. (NCT05761171)
DESCRIPTION:Revumenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study o
 f Revumenib in Combination With Chemotherapy for Patients Diagnosed With R
 elapsed or Refractory Leukemia\nEstimated primary completion: 31 December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/revumenib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05761171
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05761171-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Methotrexate: Phase 2 readout est. (NCT05761171)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 A Study of Revumenib in Combination With Chemotherapy for Patients Diagnos
 ed With Relapsed or Refractory Leukemia\nEstimated primary completion: 31 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methot
 rexate#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05761171
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07301424-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT07301424)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL\nEstimated pri
 mary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07301424
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06985485-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT06985485)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline
  Chemotherapy\nEstimated primary completion: 31 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/blinatumomab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06985485
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07105579-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT07105579)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in 
 Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantati
 on for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia\nEstimate
 d primary completion: 31 December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07105579
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07564453-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT07564453)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-
 cell Acute Lymphoblastic Leukemia\nEstimated primary completion: 31 Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/blinatumomab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075
 64453
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03934372-10794@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:ICLUSIG (Ponatinib): Phase 1/2 readout est. (NCT03934372)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 1/2\, Chronic Myeloid Leukemia.\nSt
 udy: Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent
  or Refractory Leukemias\, Lymphomas or Solid Tumors\nEstimated primary co
 mpletion: 1 February 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ponatinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT03934372
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04747912-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Methotrexate: Phase 2 readout est. (NCT04747912)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic L
 eukemia With Inotuzumab Ozogamicin (InO)\nEstimated primary completion: 1 
 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methotrex
 ate#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04747912
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04747912-10794@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:ICLUSIG (Ponatinib): Phase 2 readout est. (NCT04747912)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 2\, Acute Lymphoblastic Leukemia.\n
 Study: Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphobl
 astic Leukemia With Inotuzumab Ozogamicin (InO)\nEstimated primary complet
 ion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/po
 natinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04747912
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03286634-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Methotrexate: Phase 2 readout est. (NCT03286634)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016\nEstimated primary co
 mpletion: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/methotrexate#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT03286634
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06533748-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06533748)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphobla
 stic Leukemia and Lymphoma\nEstimated primary completion: May 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06533748
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06533748-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT06533748)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphobla
 stic Leukemia and Lymphoma\nEstimated primary completion: May 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/blinatumomab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06533748
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07643103-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Methotrexate: Phase 2 readout est. (NCT07643103)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adu
 lt Ph-Negative B-ALL: A Prospective Umbrella Trial\nEstimated primary comp
 letion: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 methotrexate#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07643103
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07643103-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT07643103)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adu
 lt Ph-Negative B-ALL: A Prospective Umbrella Trial\nEstimated primary comp
 letion: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 blinatumomab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07643103
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07840976-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT07840976)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult
  Ph+ B-ALL\nEstimated primary completion: 31 May 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07840976
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04546399-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Methotrexate: Phase 2 readout est. (NCT04546399)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Pa
 tients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B
 -ALL)\nEstimated primary completion: 30 June 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04546399
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04546399-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT04546399)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Pa
 tients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B
 -ALL)\nEstimated primary completion: 30 June 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04546399
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04530565-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Methotrexate: Phase 3 readout est. (NCT04530565)
DESCRIPTION:Methotrexate\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumom
 ab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblasti
 c Leukemia in Adults\nEstimated primary completion: 1 July 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04530565
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04530565-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Blinatumomab: Phase 3 readout est. (NCT04530565)
DESCRIPTION:Blinatumomab\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumom
 ab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblasti
 c Leukemia in Adults\nEstimated primary completion: 1 July 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/blinatumomab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04530565
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04530565-10794@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:ICLUSIG (Ponatinib): Phase 3 readout est. (NCT04530565)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 3\, Acute Lymphoblastic Leukemia.\n
 Study: Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Bli
 natumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymph
 oblastic Leukemia in Adults\nEstimated primary completion: 1 July 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/ponatinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT04530565
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03643276-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20280714
DTEND;VALUE=DATE:20280715
SUMMARY:Methotrexate: Phase 3 readout est. (NCT03643276)
DESCRIPTION:Methotrexate\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 Treatment Protocol for Children and Adolescents With Acute Lymphoblastic L
 eukemia - AIEOP-BFM ALL 2017\nEstimated primary completion: 14 July 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT03643276
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03643276-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20280714
DTEND;VALUE=DATE:20280715
SUMMARY:Blinatumomab: Phase 3 readout est. (NCT03643276)
DESCRIPTION:Blinatumomab\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 Treatment Protocol for Children and Adolescents With Acute Lymphoblastic L
 eukemia - AIEOP-BFM ALL 2017\nEstimated primary completion: 14 July 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/blinatumomab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT03643276
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07224100-10794@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:ICLUSIG (Ponatinib): Phase 2 readout est. (NCT07224100)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 2\, Acute Lymphoblastic Leukemia.\n
 Study: Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for th
 e Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymp
 hoblastic Leukemia/Lymphoma\nEstimated primary completion: 31 July 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ponatinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07224100
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04067336-2835@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20281016
DTEND;VALUE=DATE:20281017
SUMMARY:Ziftomenib: Phase 1/2 readout est. (NCT04067336)
DESCRIPTION:Ziftomenib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: First 
 in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leuke
 mia\nEstimated primary completion: 16 October 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ziftomenib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04067336
URL:https://assetmemo.bio/drug/ziftomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00501826-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Methotrexate: Phase 2 readout est. (NCT00501826)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Combination Chemotherapy and Nelarabine in Treating Patients With T-cell A
 cute Lymphoblastic Leukemia or Lymphoblastic Lymphoma\nEstimated primary c
 ompletion: 31 October 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/methotrexate#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT00501826
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02877303-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Methotrexate: Phase 2 readout est. (NCT02877303)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Blinatumomab\, Inotuzumab Ozogamicin\, and Combination Chemotherapy as Fro
 ntline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia\nE
 stimated primary completion: 1 November 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT02877303
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02877303-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT02877303)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Blinatumomab\, Inotuzumab Ozogamicin\, and Combination Chemotherapy as Fro
 ntline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia\nE
 stimated primary completion: 1 November 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT02877303
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05848687-2835@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ziftomenib: Phase 1/2 readout est. (NCT05848687)
DESCRIPTION:Ziftomenib\, phase 1/2\, Acute Lymphoblastic Leukemia.\nStudy: 
 TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II\nEs
 timated primary completion: December 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/ziftomenib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05848687
URL:https://assetmemo.bio/drug/ziftomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05848687-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Methotrexate: Phase 1/2 readout est. (NCT05848687)
DESCRIPTION:Methotrexate\, phase 1/2\, Acute Lymphoblastic Leukemia.\nStudy
 : TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II\n
 Estimated primary completion: December 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05848687
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05848687-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Blinatumomab: Phase 1/2 readout est. (NCT05848687)
DESCRIPTION:Blinatumomab\, phase 1/2\, Acute Lymphoblastic Leukemia.\nStudy
 : TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II\n
 Estimated primary completion: December 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05848687
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03970096-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Methotrexate: Phase 2 readout est. (NCT03970096)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell T
 ransplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)\n
 Estimated primary completion: 31 December 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03970096
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06317662-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06317662)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-ca
 ncer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for In
 fants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukem
 ia\nEstimated primary completion: 31 December 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06317662
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07301138-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Methotrexate: Phase 2 readout est. (NCT07301138)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged 
 and Pre-B Acute Lymphoblastic Leukemia Patients\nEstimated primary complet
 ion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/methotrexate#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07301138
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06317662-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT06317662)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-ca
 ncer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for In
 fants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukem
 ia\nEstimated primary completion: 31 December 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06317662
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07313852-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Blinatumomab: Phase 1/2 readout est. (NCT07313852)
DESCRIPTION:Blinatumomab\, phase 1/2\, Acute Lymphoblastic Leukemia.\nStudy
 : A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymph
 oblastic Leukemia\nEstimated primary completion: January 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/blinatumomab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07313852
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07356154-2841@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20290116
DTEND;VALUE=DATE:20290117
SUMMARY:Revumenib: Phase 1/2 readout est. (NCT07356154)
DESCRIPTION:Revumenib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Study
  of Revumenib and Mezigdomide in People With Leukemia\nEstimated primary c
 ompletion: 16 January 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/revumenib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07356154
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07400029-10865@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Aucatzyl (obecabtagene autoleucel): Phase 2 readout est. (NCT074000
 29)
DESCRIPTION:Aucatzyl (obecabtagene autoleucel)\, phase 2\, Acute Lymphoblas
 tic Leukemia.\nStudy: A Study of Obecabtagene Autoleucel in People With B-
 cell Acute Lymphoblastic Leukemia\nEstimated primary completion: February 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/obecabtagene-au
 toleucel#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07400029
URL:https://assetmemo.bio/drug/obecabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06918431-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20290330
DTEND;VALUE=DATE:20290331
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06918431)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of H
 igh-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymph
 oblastic Lymphoma\nEstimated primary completion: 30 March 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06918431
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04404660-10865@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Aucatzyl (obecabtagene autoleucel): Phase 1/2 readout est. (NCT0440
 4660)
DESCRIPTION:Aucatzyl (obecabtagene autoleucel)\, phase 1/2\, Acute Lymphobl
 astic Leukemia.\nStudy: A Study of CD19 Targeted CAR T Cell Therapy in Adu
 lt Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaem
 ia (ALL)\nEstimated primary completion: 30 June 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/obecabtagene-autoleucel#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04404660
URL:https://assetmemo.bio/drug/obecabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06061094-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT06061094)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy\, Imat
 inib or Ponatinib\, Blinatumomab and SCT\nEstimated primary completion: 1 
 July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/blinatumom
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6061094
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06061094-10794@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:ICLUSIG (Ponatinib): Phase 2 readout est. (NCT06061094)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 2\, Acute Lymphoblastic Leukemia.\n
 Study: Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy
 \, Imatinib or Ponatinib\, Blinatumomab and SCT\nEstimated primary complet
 ion: 1 July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pon
 atinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06061094
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04994717-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20290907
DTEND;VALUE=DATE:20290908
SUMMARY:Blinatumomab: Phase 3 readout est. (NCT04994717)
DESCRIPTION:Blinatumomab\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy V
 ersus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed 
 Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia\nEstim
 ated primary completion: 7 September 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04994717
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764238-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Blinatumomab: Phase 2/3 readout est. (NCT06764238)
DESCRIPTION:Blinatumomab\, phase 2/3\, Acute Lymphoblastic Leukemia.\nStudy
 : Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol\nEs
 timated primary completion: 31 December 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06764238
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06882057-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Blinatumomab: Phase 2/3 readout est. (NCT06882057)
DESCRIPTION:Blinatumomab\, phase 2/3\, Acute Lymphoblastic Leukemia.\nStudy
 : Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol\nEstimated primar
 y completion: 31 December 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/blinatumomab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06882057
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227584-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Methotrexate: Phase 2 readout est. (NCT07227584)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 ALL Backbone in AYAs\nEstimated primary completion: 31 July 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07227584
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227584-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT07227584)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 ALL Backbone in AYAs\nEstimated primary completion: 31 July 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/blinatumomab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07227584
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07192237-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20301012
DTEND;VALUE=DATE:20301013
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT07192237)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumom
 ab in Patients With Measurable Residual Disease Positive B-cell Acute Lymp
 hoblastic Leukemia\nEstimated primary completion: 12 October 2030. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/blinatumomab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07192237
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06128070-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20301122
DTEND;VALUE=DATE:20301123
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06128070)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft V
 ersus Host Disease in Pediatric and Young Adult Patients Undergoing Alloge
 neic Hematopoietic Cell Transplant for Acute Myeloid Leukemia\, Acute Lymp
 hoblastic Leukemia\, or Myelodysplastic Syndrome\nEstimated primary comple
 tion: 22 November 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/methotrexate#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06128070
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06124157-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20301201
DTEND;VALUE=DATE:20301202
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06124157)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy T
 reatment With Blinatumomab for Children\, Adolescents\, and Young Adults W
 ith Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chrom
 osome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)\nEstimate
 d primary completion: 1 December 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06124157
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06124157-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20301201
DTEND;VALUE=DATE:20301202
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT06124157)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy T
 reatment With Blinatumomab for Children\, Adolescents\, and Young Adults W
 ith Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chrom
 osome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)\nEstimate
 d primary completion: 1 December 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06124157
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07134088-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20310306
DTEND;VALUE=DATE:20310307
SUMMARY:Blinatumomab: Phase 1/2 readout est. (NCT07134088)
DESCRIPTION:Blinatumomab\, phase 1/2\, Acute Lymphoblastic Leukemia.\nStudy
 : A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B
 -Cell Precursor Acute Lymphoblastic Leukemia\nEstimated primary completion
 : 6 March 2031. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/blina
 tumomab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07134088
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07636564-2841@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20310416
DTEND;VALUE=DATE:20310417
SUMMARY:Revumenib: Phase 2 readout est. (NCT07636564)
DESCRIPTION:Revumenib\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: Tes
 ting Blinatumomab With or Without Revumenib in Patients With B-cell Acute 
 Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment\nEst
 imated primary completion: 16 April 2031. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/revumenib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07636564
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07636564-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20310416
DTEND;VALUE=DATE:20310417
SUMMARY:Methotrexate: Phase 2 readout est. (NCT07636564)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acu
 te Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment\n
 Estimated primary completion: 16 April 2031. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07636564
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07636564-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20310416
DTEND;VALUE=DATE:20310417
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT07636564)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acu
 te Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment\n
 Estimated primary completion: 16 April 2031. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07636564
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07153796-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Blinatumomab: Phase 1/2 readout est. (NCT07153796)
DESCRIPTION:Blinatumomab\, phase 1/2\, Acute Lymphoblastic Leukemia.\nStudy
 : A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Bli
 natumomab in Combination With Low Intensity Chemotherapy in Older Patients
  With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia\nEstimated prima
 ry completion: 30 September 2031. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07153796
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07178912-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT07178912)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverem
 batinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR:
 :ABL1 Positive Acute Lymphoblastic Leukemia (ALL)\nEstimated primary compl
 etion: 30 September 2031. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/blinatumomab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07178912
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223190-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20311230
DTEND;VALUE=DATE:20311231
SUMMARY:Blinatumomab: Phase 3 readout est. (NCT07223190)
DESCRIPTION:Blinatumomab\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly D
 iagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia\nEstim
 ated primary completion: 30 December 2031. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07223190
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03959085-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20320331
DTEND;VALUE=DATE:20320401
SUMMARY:Methotrexate: Phase 3 readout est. (NCT03959085)
DESCRIPTION:Methotrexate\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients
  With High-Risk B-ALL\, Mixed Phenotype Acute Leukemia\, and B-LLy\nEstima
 ted primary completion: 31 March 2032. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT03959085
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03959085-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20320331
DTEND;VALUE=DATE:20320401
SUMMARY:Blinatumomab: Phase 3 readout est. (NCT03959085)
DESCRIPTION:Blinatumomab\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients
  With High-Risk B-ALL\, Mixed Phenotype Acute Leukemia\, and B-LLy\nEstima
 ted primary completion: 31 March 2032. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT03959085
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05827549-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT05827549)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Evaluation of Treatment Efficacy According to Risk Group in Relapsed Child
 hood Acute Lymphoblastic Leukemia\nEstimated primary completion: 31 Decemb
 er 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/blinatumomab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT058
 27549
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07387926-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20330919
DTEND;VALUE=DATE:20330920
SUMMARY:Methotrexate: Phase 1/2 readout est. (NCT07387926)
DESCRIPTION:Methotrexate\, phase 1/2\, Acute Lymphoblastic Leukemia.\nStudy
 : Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Rel
 apse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acu
 te Lymphoblastic Leukemia (ALL)\nEstimated primary completion: 19 Septembe
 r 2033. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/methotrexate#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0738
 7926
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07387926-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20330919
DTEND;VALUE=DATE:20330920
SUMMARY:Blinatumomab: Phase 1/2 readout est. (NCT07387926)
DESCRIPTION:Blinatumomab\, phase 1/2\, Acute Lymphoblastic Leukemia.\nStudy
 : Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Rel
 apse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acu
 te Lymphoblastic Leukemia (ALL)\nEstimated primary completion: 19 Septembe
 r 2033. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/blinatumomab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0738
 7926
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06099366-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20331231
DTEND;VALUE=DATE:20340101
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06099366)
DESCRIPTION:Methotrexate\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in
  Children\nEstimated primary completion: 31 December 2033. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/methotrexate#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06099366
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06860269-5633@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20350315
DTEND;VALUE=DATE:20350316
SUMMARY:Blinatumomab: Phase 2/3 readout est. (NCT06860269)
DESCRIPTION:Blinatumomab\, phase 2/3\, Acute Lymphoblastic Leukemia.\nStudy
 : A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic
  Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) i
 n Frontline Therapy of Adults With Acute Lymphoblastic Leukemia\nEstimated
  primary completion: 15 March 2035. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06860269
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06860269-10794@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20350315
DTEND;VALUE=DATE:20350316
SUMMARY:ICLUSIG (Ponatinib): Phase 2/3 readout est. (NCT06860269)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 2/3\, Acute Lymphoblastic Leukemia.
 \nStudy: A 3-cohort Randomized Study Evaluating the Role of New Immunother
 apeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (
 HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia\nEs
 timated primary completion: 15 March 2035. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/ponatinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06860269
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07072585-3826@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20350901
DTEND;VALUE=DATE:20350902
SUMMARY:Methotrexate: Phase 2/3 readout est. (NCT07072585)
DESCRIPTION:Methotrexate\, phase 2/3\, Acute Lymphoblastic Leukemia.\nStudy
 : Testing the Addition of Daratumumab to Chemotherapy for Treating Patient
 s With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Ly
 mphoblastic Lymphoma (T-LL)\nEstimated primary completion: 1 September 203
 5. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/methotrexate#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07072585
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
